top of page

Where Science Sparks Business in Medicines

image.png

Co-producers

image.png
image.png
image.png

BioVerse Episode 24 - The Biotech Landscape of Japan and Singapore

BioVerse
BioVerse Episode 24 - The Biotech Landscape of Japan and Singapore
BioVerse Episode 24 - The Biotech Landscape of Japan and Singapore

BioVerse Episode 24 - The Biotech Landscape of Japan and Singapore

01:09:54
BioVerse Episode 23 - Why is HKEX Having a Biotech Boom?

BioVerse Episode 23 - Why is HKEX Having a Biotech Boom?

01:20:23
BioVese Episode 22 - Asian Biotechies Recap ASCO & BIO 2025

BioVese Episode 22 - Asian Biotechies Recap ASCO & BIO 2025

01:35:52
BioVerse Episode 21 - AACR2205 Recap & Asian Biotech Innovation Boom

BioVerse Episode 21 - AACR2205 Recap & Asian Biotech Innovation Boom

01:49:56
BioVerse Episode 20 - The Trends of Asia-to-Europe Pharmaceutical Licensing Deals

BioVerse Episode 20 - The Trends of Asia-to-Europe Pharmaceutical Licensing Deals

01:09:00
BioVerse Episode 18 - China-to-West: Deals Shaping the Immuno-Oncology Landscape

BioVerse Episode 18 - China-to-West: Deals Shaping the Immuno-Oncology Landscape

58:38
BioVerse Episode 17 - JPM2025 Recap - News, Trends, Sentiment, and China Trade

BioVerse Episode 17 - JPM2025 Recap - News, Trends, Sentiment, and China Trade

01:14:15
BioVerse Episode 16 - Asian Biotechies Walk Into BioVerse to Review 2024 in Biotech

BioVerse Episode 16 - Asian Biotechies Walk Into BioVerse to Review 2024 in Biotech

01:28:05
BioVerse Episode 15 - M&A, The Ultimate Exit of Biotechs

BioVerse Episode 15 - M&A, The Ultimate Exit of Biotechs

01:17:13
BioVerse Episode 14 - The Current Global Trends In Biotech IPOs

BioVerse Episode 14 - The Current Global Trends In Biotech IPOs

01:23:16
BioVerse Episode 13 - The Current Trends of R&D and Deal-making in Immunology & Inflammation

BioVerse Episode 13 - The Current Trends of R&D and Deal-making in Immunology & Inflammation

01:08:37
BioVerse episode 12 - Artificial Intelligence in Drug Development

BioVerse episode 12 - Artificial Intelligence in Drug Development

01:31:54
BioVerse Episode 11 - China Biotech Out-licensing 2.0: Global Vision, Local Execution (Chinese)

BioVerse Episode 11 - China Biotech Out-licensing 2.0: Global Vision, Local Execution (Chinese)

02:24:51
Bioverse Episode 10 - The Winners, Losers, and Dark Horses of ASCO24 & BIO2024 tidbits

Bioverse Episode 10 - The Winners, Losers, and Dark Horses of ASCO24 & BIO2024 tidbits

01:41:35
Bioverse Episode 9 - The Essential Role of CMC in ADC, Radiopharmaceutical, and Cell & Gene Therapy

Bioverse Episode 9 - The Essential Role of CMC in ADC, Radiopharmaceutical, and Cell & Gene Therapy

01:03:18
Bioverse episode 8 - Recap of AACR 2024

Bioverse episode 8 - Recap of AACR 2024

01:33:18
Bioverse episode 7 - Leverage Commercial Lens to Enable Successful Drug Development and Deal-making

Bioverse episode 7 - Leverage Commercial Lens to Enable Successful Drug Development and Deal-making

01:11:12
Bioverse episode 6 - Physician Scientists' Checklists to Conduct Successful Clinical Development

Bioverse episode 6 - Physician Scientists' Checklists to Conduct Successful Clinical Development

49:16
Bioverse episode 5 - JPM24 Recap and 2004 global outlook, from the lens of China biotech

Bioverse episode 5 - JPM24 Recap and 2004 global outlook, from the lens of China biotech

59:36
BioVerse episode 4 - How to survive and thrive in a biotech winter, a chat with Les Funtleyder

BioVerse episode 4 - How to survive and thrive in a biotech winter, a chat with Les Funtleyder

01:01:03
bottom of page